April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Subconjunctival Delivery of a Neuroprotectant using Fibrin Sealant
Author Affiliations & Notes
  • Jeffrey H. Boatright
    Ophthalmology, Emory University School of Med, Atlanta, Georgia
  • Cecilia M. Rodrigues
    Centro de Patogénese Molecular, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal
  • Sheree S. Mosley
    Ophthalmology, Emory University School of Med, Atlanta, Georgia
  • Esther Kim
    Ophthalmology, Emory University School of Med, Atlanta, Georgia
  • Clifford J. Steer
    Medicine, Genetics, Cell Biology, and Development, University of Minnesota Medical School, Minneapolis, Minnesota
  • John M. Nickerson
    Ophthalmology, Emory University School of Med, Atlanta, Georgia
  • Henry F. Edelhauser
    Ophthalmology, Emory University School of Med, Atlanta, Georgia
  • Footnotes
    Commercial Relationships  Jeffrey H. Boatright, None; Cecilia M. Rodrigues, None; Sheree S. Mosley, None; Esther Kim, None; Clifford J. Steer, None; John M. Nickerson, None; Henry F. Edelhauser, None
  • Footnotes
    Support  The Abraham J. and Phyllis Katz Foundation, Foundation Fighting Blindness, Research to Prevent Blindness, NIH NEI R01EY014026, R01EY016470, R24EY017045, P30EY006360
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4355. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jeffrey H. Boatright, Cecilia M. Rodrigues, Sheree S. Mosley, Esther Kim, Clifford J. Steer, John M. Nickerson, Henry F. Edelhauser; Subconjunctival Delivery of a Neuroprotectant using Fibrin Sealant. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4355.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine whether subconjunctival injection of tauroursodeoxycholic acid (TUDCA) mixed in fibrin sealant results in tissue concentrations previously shown to be protective in retinal degeneration models.

Methods: : 50 ul of TUDCA (52 mg/ml) in fibrin sealant was injected into the subconjunctival space of one eye of each of 20 rats. The other eye was injected with fibrin sealant alone. Other rats were injected i.p. with 500 mg/kg TUDCA every 3 days for two weeks, a proven protective dosing regimen. Total UDCA levels were assessed by gas chromatography.

Results: : Total UDCA in retinas from eyes injected with fibrin sealant/TUDCA was 16.7 nmol/g one day after injection and 10.3 nmol/g seven days after injection. UDCA was undetectable in control retinas. Total serum UDCA was 0.86 umol/L one day after injection and 0.065 umol/L after seven days. For rats injected i.p. with vehicle, steady-state retina UDCA was 0.06 nmol/g and serum UDCA was 0.50 umol/L. For rats injected i.p. with TUDCA, steady-state retina UDCA was 7.1 nmol/g and serum UDCA was 6.2 umol/L.

Conclusions: : The results indicate that a single subconjunctival injection of TUDCA in fibrin sealant results in minimal serum levels of the compound while providing retina tissue levels of the drug well above those provided by a systemic injection dosage regimen that is protective in models of retinal degeneration.

Keywords: neuroprotection • drug toxicity/drug effects • retinal degenerations: cell biology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×